ABSTRACT
INTRODUCTION Polysaccharide-protein conjugate vaccines are established tools for the prevention of serious disease caused by encapsulated bacteria. Conjugate vaccines to prevent disease caused by Haemophilus influenzae type b (Hib) and serogroup C meningococcus (MCC) have been used in routine national immunization programs over a number of years. In this chapter, we review development and implementation of these vaccines, and present data from industrialized countries demonstrating their striking impact and the continued need for effective enhanced surveillance post-vaccine introduction.
